Skip to main content
Signal8
Launch Terminal

Neuronetics, Inc. (STIM)

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Neuronetics, Inc. logo

Neuronetics, Inc.

NASDAQ:STIMHealthcare
-5.46%$2.25
AH$2.29+1.69%vs close
Mkt Cap$171.44M
Float41.53M
O/S76.2M
Vol
$ Vol
RVOL
Inst Own48.8%
SI17.4%
Earnings
Dilution
Neuronetics, Inc. logoNASDAQ:STIM$2.25-5.46%
Phase Distribution
13 lead-sponsored trials·4 active·7 completed
Phase 31
Not applicable12
(15 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting2
Completed7
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder

    Repetitive Transcranial Magnetic Stimulation

    Major Depressive Disorder

    Enrollment
    286
    Start
    Jan 2004
    Primary Completion
    Nov 2005
    Completion
    Nov 2005
    NCT00104611
  • Observational
    Completed

    NeuroStar TMS Therapy System: Utilization and Outcomes

    -

    Major Depressive Disorder

    Enrollment
    307
    Start
    Mar 2010
    Primary Completion
    Sep 2012
    Completion
    Sep 2012
    NCT01114477
  • Not applicable
    Completed

    Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

    NeuroStar TMS

    Major Depressive Disorder

    Enrollment
    67
    Start
    Aug 2011
    Primary Completion
    Sep 2013
    Completion
    Jul 2014
    NCT01415154
  • Not applicable
    Terminated

    Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

    NeuroStar Transcranial Magnetic Stimulation (TMS)

    Depression, Postpartum

    Enrollment
    25
    Start
    Dec 2013
    Primary Completion
    Jul 2015
    Completion
    Aug 2015
    NCT01842542
  • Not applicable
    Completed

    Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

    Active NeuroStar® Transcranial Magnetic Stimulation (TMS), Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)

    Major Depressive Disorder

    Enrollment
    112
    Start
    Oct 2015
    Primary Completion
    Jan 2018
    Completion
    Dec 2018
    NCT02586688
  • Observational
    Withdrawn

    Treatment of Major Depressive Disorder in the UK Using TMS Therapy

    Transcranial Magnetic Stimulator

    Major Depressive Disorder

    Enrollment
    0
    Start
    Mar 2020est.
    Primary Completion
    Feb 2022est.
    Completion
    Feb 2022est.
    NCT04217837
  • Not applicable
    Completed

    Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

    repetitive Transcranial Magnetic Stimulation

    Major Depressive Disorder

    Enrollment
    40
    Start
    Nov 2022
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT05535062
  • Observational
    Completed

    Retrospective TMS Therapy for Adults With MDD

    TMS

    Major Depressive Disorder (MDD)

    Enrollment
    6,456
    Start
    Nov 2008
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT05541302
  • Not applicable
    Active, not recruiting

    Symptom Evaluation Following Repetitive Transcranial Magnetic Stimulation

    rTMS

    Neurologic Symptoms

    Enrollment
    20
    Start
    May 2024
    Primary Completion
    Apr 2025
    Completion
    Dec 2027est.
    NCT06429748
  • Observational
    Completed

    A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents

    Transcranial Magnetic Stimulation

    MDD

    Enrollment
    7,690
    Start
    May 2023
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT06699940
  • Observational
    Recruiting

    Retrospective Analyses of TrakStar Database

    NeuroStar Advanced TMS Therapy System

    Depression, Obsessive-Compulsive Disorder +1

    Enrollment
    156,000
    Start
    Feb 2025
    Primary Completion
    Dec 2035est.
    Completion
    Dec 2035est.
    NCT06917339
  • Observational
    Recruiting

    Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

    Patients treated with Esketamine

    Depression, OCD +1

    Enrollment
    12,000
    Start
    May 2025
    Primary Completion
    Dec 2035est.
    Completion
    Dec 2035est.
    NCT06997549
  • Not applicable
    Active, not recruiting

    Accelerated TMS for MDD

    TMS

    Major Depressive Disorder

    Enrollment
    50
    Start
    Aug 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT07147218
Search ClinicalTrials.gov for “Neuronetics”